Is there a role for differentiating therapy in non-APL AML?
- PMID: 21130414
- PMCID: PMC5884682
- DOI: 10.1016/j.beha.2010.09.014
Is there a role for differentiating therapy in non-APL AML?
Abstract
Differentiation therapy with all-trans retinoic acid has been a very successful therapeutic strategy in acute promyelocytic leukemia (APL), but the value of differentiation therapy in acute myeloid leukemia (AML) remains to be determined. A number of current treatments, such as tyrosine kinase inhibitors, cytokines, and epigenetic agents, induce differentiation of leukemic cells to some extent, but differentiation is not the main goal of these treatments. Forcing expression of certain transcription factors, such as C/EBP, has also been useful in inducing differentiation in cell lines and in murine models, but an effective way to force expression of these genes in humans is yet to be discovered.
Copyright © 2010. Published by Elsevier Ltd.
Figures
References
-
- Metcalf D. Clonal extinction of myelomonocytic leukemic cells by serum from mice injected with endotoxin. Int J Cancer. 1980;25:225–33. - PubMed
-
- Metcalf D. Clonal analysis of the action of GM-CSF on the proliferation and differentiation of myelomonocytic leukemic cells. Int J Cancer. 1979;24:616–23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
